comparemela.com

Latest Breaking News On - Jerald sadoff - Page 1 : comparemela.com

Single-dose COVID-19 vaccine effective against variants, study says

In the three months since Johnson & Johnson’s COVID-19 vaccine received emergency use authorization from the U.S. Food and Drug Administration, more than 10 million Americans have received the vaccine, according to the Centers for Disease Control and Prevention. The single-shot viral vector vaccine developed in collaboration with Beth Israel Deaconess Medical Center (BIDMC) immunologist Dan Barouch was authorized for use based on clinical trial data showing strong clinical efficacy against symptomatic COVID-19 in the United States, Latin America and South Africa. In a new study published in Nature, Barouch, director of BIDMC’s Center for Virology and Vaccine Research, and colleagues report on the antibody and cellular immune responses generated by the Ad26.COV2.S vaccine against the original viral strain and against SARS-CoV-2 variants of concern. The team found that this vaccine induced immune responses against all the viral variants.  

Single-Shot COVID-19 Vaccine Generates Robust Immune Responses Against COVID-19 Variants

BOSTON – In the three months since Johnson & Johnson's COVID-19 vaccine received emergency use authorization from the U.S. Food and Drug Administration,.

Ad26 COV2-S Vaccine Seems Safe, Immunogenic for SARS-CoV-2

Jan 14, 2021 WEDNESDAY, Jan. 13, 2021 (HealthDay News) A candidate vaccine, Ad26.COV2.S, with a recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized severe acute respiratory syndrome coronavirus 2 spike protein is safe and immunogenic, according to a study published online Jan. 13 in the New England Journal of Medicine. Jerald Sadoff, M.D., from Janssen Vaccines and Prevention in Leiden, Netherlands, and colleagues conducted a phase 1-2a trial involving healthy adults ages 18 to 55 years (cohort 1) and 65 years or older (cohort 3). Participants were randomly assigned to receive Ad26.COV2.S at a low dose or high dose or placebo in a single-dose or two-dose schedule.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.